



World Health
Organization

GUIDELINES



CONSOLIDATED HIV STRATEGIC
INFORMATION GUIDELINES

DRIVING IMPACT THROUGH PROGRAMME MONITORING AND MANAGEMENT

APRIL 2020

HIV STRATEGIC INFORMATION FOR IMPACT

CONSOLIDATED HIV STRATEGIC
INFORMATION GUIDELINES

**DRIVING IMPACT
THROUGH PROGRAMME
MONITORING AND
MANAGEMENT**

APRIL 2020

Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management

ISBN 978-92-4-000073-5 (electronic version)

ISBN 978-92-4-000074-2 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020. Licence: **CC BY-NC-SA 3.0 IGO**.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by 400 Communication

CONTENTS

Acknowledgements	viii
Abbreviations and acronyms	xii
Glossary	xiv
Executive summary	xvi
Part 1. Strategic information: a consolidated framework	1
1.1 Introduction	2
1.1.1 Selection of indicators	3
1.1.2 Process of development	4
1.1.3 Intended audiences of this guideline	5
1.1.4 Organization of the document	5
1.2 The strategic framework	6
1.2.1 The HIV results chain	6
1.2.2 The HIV cascade of services – improving linkages from testing to prevention and treatment	7
1.2.3 Moving from aggregate to individual-level data: enabling patient-centred monitoring and case surveillance	9
1.2.4 Health system building blocks	10
1.3 Using routine data reviews for programme improvement	12
1.3.1 Application of routine data reviews at different levels	13
1.3.2 Core analysis for routine data reviews	14
1.3.3 Use cases for more in-depth data review	17
1.3.4 Establishing systems for routine data reviews	19
1.3.5 Electronic health information systems to support routine data reviews	20
Part 2. Strong SI systems for effective decision-making	21
2.1 Prioritizing programme indicators	22
2.2 Country customization of national core and priority indicators	25
2.2.1 Criteria for selecting additional indicators	26
2.2.2 Differentiated programmes	26
2.2.3 Assessing the balance of indicator sets	27
2.3 Important considerations in reporting and use of aggregate data	28
2.3.1 Appropriate denominators for coverage indicators	28
2.3.2 Interpreting and using model-based denominators	29
2.3.3 Denominators based on key population size	30
2.3.4 Time periods for indicator definitions	31

2.4 Data disaggregation to improve programming	31
2.4.1 Why disaggregate?	31
2.4.2 How to disaggregate reported indicators	33
2.4.3 Additional considerations for disaggregating data	35
2.5 Strengthening the sources of strategic information	36
2.5.1 Types of data sources	37
2.5.2 Use and interpretation of routine facility data	37
2.5.3 Inclusion of community-based service data	38
2.5.4 More effective use of population-based survey data	39
2.5.5 Optimizing the use of other data sources	40
2.5.6 Ethical considerations for health information systems	41
2.6 Data quality review and assessment	42
2.7 Evaluation and operational research	43
Part 3. Recommended indicators: national core and priority	45
3.1 Reducing new infections	46
3.1.1 Condom use	46
3.1.2 Pre-exposure prophylaxis (PrEP)	48
3.2 Knowing status and linkage to treatment	50
3.3 Treatment and VL suppression (adult)	53
3.3.1 Treatment and ART toxicity	53
3.3.2 Viral suppression	56
3.4 Reduced mortality – TB/HIV	58
3.5 Preventing vertical transmission	61
3.6 Reducing co-morbidity – STI	63
3.7 Zero discrimination	66
3.8 Special population groups	67
3.8.1 Key population groups	67
3.8.2 Paediatric and adolescent HIV care and treatment	70
3.8.3 Adolescent girls and young women	73
3.9 Differentiated use	74
3.9.1 Voluntary medical male circumcision	74
3.9.2 Injection safety	76
3.9.3 Blood safety	76
3.9.4 Tuberculosis/HIV	78
3.9.5 Hepatitis	78

3.10 Burden and impact indicators	79
3.11 Detailed descriptions of the national indicators	80
PR.1 Condom use (KP & Gen pop)	86
PR.2 Condoms distributed	88
PR.3 PrEP uptake	89
PR.4 PrEP continuation (at 3 months)	90
PR.5 Currently on PrEP	92
TL.1 People living with HIV who know their HIV status (first 95)	93
TL.2 HTS testing volume and positivity	95
TL.3 Linkage to ART	96
TL.4 HTS index testing and partner notification	97
TL.5 Number of individual HIVST kits distributed	99
TL.6 Know their status (key population)	100
AV.1 People living with HIV on ART	101
AV.2 Total attrition from ART	103
AV.3 People living with HIV who have suppressed VL	105
AV.4 New ART patients	106
AV.5 Late ART initiation	107
AV.6 Viral load testing coverage	108
AV.7 Early viral load testing (at 6 months)	109
AV.8 Appropriate second VL test	110
AV.9 ARV toxicity prevalence	111
TB.1 TPT initiation	112
TB.2 TPT completion	113
TB.3 TB diagnostic testing type	114
TB.4 People living with HIV with active TB disease	115
VT.1 Viral suppression at labour and delivery	116
VT.2 EID coverage	117
VT.3 Infant ARV prophylaxis coverage	118
VT.4 ART coverage in pregnant women	119
VT.5 ART coverage in breastfeeding mothers	120
VT.6 Final outcome of PMTCT	121
ST.1 Syphilis screening coverage (in ANC)	122
ST.2 Syphilis treatment coverage (in ANC)	123
ST.3 Cervical cancer screening among women living with HIV	124

SD.1 Avoidance of health care due to stigma and discrimination (key populations)	125
SD.2 Avoidance of health care due to stigma and discrimination (people living with HIV)	126
KP.1 Coverage of HIV prevention (KP)	127
KP.2 Needles and syringes distributed	129
KP.3 Coverage of OST	130
KP.4 Safe injecting practices (people who inject drugs)	131
GW.1 Adolescent girls and young women HIV/SRH integration	132
DfC.1 VMMC scale-up	133
DfC.2 VMMC adverse events	134
DfI.1 Facility-level injection safety	135
DfI.2 Rate of unsafe injections per person	136
DfB.1 Facility-level blood safety	137
DfB.2 Quality-assured blood testing	138
DfT.1 TB screening coverage among new ART patients	139
DfT.2 TB symptom-screened positive among new ART patients	140
DfT.3 TB testing among those symptom-screened positive	141
DfT.4 TB diagnosis among those tested for TB	142
DfT.5 TB treatment initiation among diagnosed	143
DfH.1 HCV screening coverage	144
DfH.2 HCV treatment coverage	145
BI.1 People living with HIV	146
BI.2 HIV prevalence among KP	147
BI.3 New HIV infections (per 1000 population)	148
BI.4 Final MTCT rate	149
BI.5 AIDS mortality	150

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24669

